Matthew Laight is an established name in the life sciences market report sources, with over 25 years of experience with contentious patent proceedings.
Matthew specialises in both contentious and non-contentious matters, advising clients across a broad range of sectors including electronics, pharmaceuticals, communications, information technology, media, broadcasting, and food and beverages.
Matthew heads the Bird & Bird intellectual property (IP) group in Asia.
With more than 25 years experience in representing multinational companies in China and across Asia, Matthew advises on all aspects of IP covering both contentious and non-contentious matters, including licensing and monetising IP.
He regularly advises on major IP litigation and is well known for managing complex, multi-jurisdictional disputes, working closely with our network of partner firms and developing strategies for cases across the different legal and regulatory environments in the Asia-Pacific region.
Matthew has extensive experience in IP advisory commercial matters including patents, trademarks, copyright, domain names, product safety and labelling issues.
In the past 25 years, Matthew has represented some of the world’s leading companies in the life sciences and electronics sectors. His life sciences experience includes contentious matters such as patent, trade mark and unfair competition litigation; and commercial work such as clinical trials agreements, joint promotion and joint marketing agreements, collaboration and development agreements. In the electronics sector, Matthew has been heavily involved in standards issues and the interplay between standards and patents. He has been involved in some of the leading cases relating to standard essential patents.
Matthew has a long-standing reputation as a leader in his field and continues to be ranked by the major industry publications and legal directories including, Chambers Asia-Pacific, the Asia-Pacific edition of The Legal 500, AsiaLaw, Asia IP Profiles, IAM Patent 1000, IAM Life Sciences 250, and the patents, life sciences and trademarks editions of Who’s Who Legal.